Request Demo
Last update 20 Mar 2025
Recibokibart
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Recombinant humanized anti-interleukin 36R monoclonal antibody(Huaota Biopharma) |
Target |
Action inhibitors |
Mechanism IL-36R inhibitors(Interleukin-36 receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Structure/Sequence
Sequence Code 941453118H
Source: *****
Sequence Code 941453119L
Source: *****
Related
10
Clinical Trials associated with RecibokibartCTR20244585
一项在成年健康受试者中评价HB0034的安全性、耐受性和药代动力学的随机、双盲、安慰剂对照、单/多次给药剂量递增I期研究
[Translation] A randomized, double-blind, placebo-controlled, single/multiple dose escalation phase I study to evaluate the safety, tolerability and pharmacokinetics of HB0034 in healthy adult subjects
NCT06716151
A Phase I, Randomized, Double-blind, Placebo-controlled, Single/mulit Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HB0034 in Adult Healthy Subjects
NCT06477536
A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
100 Clinical Results associated with Recibokibart
Login to view more data
100 Translational Medicine associated with Recibokibart
Login to view more data
100 Patents (Medical) associated with Recibokibart
Login to view more data
1
Literatures (Medical) associated with RecibokibartJournal of the European Academy of Dermatology and Venereology
Recibokibart, an anti‐IL ‐36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial
Letter
Author: Yang, Baoqi ; Zhang, Chunlei ; Man, Xiaoyong ; Kuang, Yehong ; Zhou, Guodong ; Zhang, Zhaoxia ; Qian, Qiaoxia ; Zhan, Yifan ; Chen, Jiaqi ; Lu, Xueyan ; Chen, Qian ; Zhu, Xiangyang ; Ma, Chi ; Li, Benke ; Ma, Xiuqiang ; Situ, Xiaolu ; Chen, Shi ; Zhang, Furen ; Su, Juan ; Feng, Yujie ; Yang, Yongming ; Wang, Jiucun
100 Deals associated with Recibokibart
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Generalized Pustular Psoriasis | Phase 3 | China | 02 Sep 2024 | |
| Colitis, Ulcerative | Phase 3 | China | - | |
| Systemic Lupus Erythematosus | Phase 3 | China | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free